Research
Neural
The effects of GLP-1 agonists on sexual desire may be overlooked due to competing influences.
Awareness of these competing influences is crucial for healthcare providers managing patients on GLP-1 agonists.
StrongSupportsmedium confidence
We then applied a biopsychosocial framework to highlight why this effect may be overlooked by GLP-1-treated patients and clinicians.
Why this rating
The claim is based on a narrative review analysis of existing literature.
Source
Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don’t ‘see’ it
Sergei Gelfand et al. · Obesity Pillars · 2025
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →